GenScript, Parkway Laboratories and Diagnostics Development Hub collaborate to provide cPass(TM) SARS-CoV-2 Neutralizing Antibody Testing Service
GenScript, Parkway Laboratories and Diagnostics Development (DxD) Hub collaborate to provide cPass(TM) SARS-CoV-2 Neutralizing Antibody Testing Service in Singapore
PR88953
SINGAPORE, April 12, 2021 /PRNewswire=KYODO JBN/ --
GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), Parkway
Laboratories and the Diagnostics Development (DxD) Hub announced their
collaboration to provide the cPass(TM) SARS-CoV-2 neutralizing antibody test in
Singapore through Parkway's panel of specialist and GP clinics.
Neutralizing antibodies are a small percentage of antibodies that bind to sites
on the virus and inhibit entry of that virus into the host. Unlike the many
COVID-19 lab-based antibody test kits commercially available, cPass(TM) can
detect functional neutralizing antibodies. Traditionally, measuring
neutralizing antibodies requires the use of live virus, cells, highly skilled
operators, and complex laboratory procedures that require several days in the
laboratory to obtain results and limit their widespread use. In contrast, the
cPass(TM) kit can be performed in most standard laboratories with a short
turnaround time (approx. 1hr). cPass(TM) is also adaptable to high throughput
and fully automated testing.
The cPass(TM) SARS-CoV-2 Neutralization Antibody Detection Kit was co-developed
by Duke-NUS Medical School (Duke-NUS), a research-intensive graduate-entry
medical school, GenScript, and DxD Hub. The kit has received provisional
authorization by the Health Sciences Authority (HSA) Singapore, CE-IVD marking
in Europe and emergency use authorization (EUA) by the U.S. Food and Drug
Administration (FDA).
"As a leading biotech company, we take it as our responsibility to contribute
in fighting COVID-19 with our technology and global collaboration with
partners. We are very glad to cooperate with Parkway and DxD in Singapore to
serve our local community with cPass(TM)," said Johnson Wang, President in
Asia-Pacific Region at GenScript.
"Parkway Laboratories has been in close partnership with DxD Hub since the
beginning of the COVID-19 pandemic as early adopters of new diagnostic
platforms that gave our frontline clinicians the necessary detection tools to
make astute clinical decisions. We are now delighted to continue this
partnership and welcome cPass(TM) into our SARS-CoV-2 diagnostic armamentarium
to provide measurement of neutralizing antibodies. This will provide valuable
information on vaccinations for our patients," said Dr Daniel Tan, Chief
Executive Officer, Parkway Laboratories.
Dr Sidney Yee, Chief Executive Officer of DxD Hub, said: "As a national
platform which aims to accelerate the translation of R&D to clinically
validated diagnostics, we are heartened to see this public-private partnership
act very quickly to make the innovative cPass(TM) diagnostic test available to
clinicians in Singapore."
Professor Wang Linfa from the Emerging Infectious Diseases Programme, Duke-NUS
Medical School who invented this assay said: "Unlike other commercially
available antibody tests which detect binding antibodies in general, the
cPass(TM) platform was invented to specifically monitor functional neutralizing
antibodies, and is the only antibody test approved by Health Science Authority
(HSA) Singapore and FDA Emergency Use Authorization (EUA) for that purpose."
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology
group. Built upon its leading gene synthesis technology, GenScript is divided
into four major platforms including the life science contract research
organization (CRO) platform, the biologics contract development and
manufacturing organization (CDMO) platform, the global cell therapy platform
and the industrial synthesis biological product platform.
GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong
Stock Exchange in 2015. GenScript's business operations span over 100 countries
and regions worldwide with legal entities located in the US, Mainland China,
Hong Kong, Japan, Singapore, the Netherlands and Ireland. GenScript provides
premium, convenient and reliable products and services for over 100,000
customers. As of December 31, 2020, GenScript had more than 4600 employees
globally, over 39% of whom hold master's and/or Ph.D. degrees. In addition,
GenScript owns a number of intellectual property rights and trade secrets,
including 146 patents and 517 pending patent applications.
Driven by the corporate mission of "making people and nature healthier through
biotechnology", GenScript strives to become the most trustworthy biotech
company in the world. As of December 31, 2020, GenScript's products or services
have been cited by 52,500 peer-reviewed journal articles worldwide.
For more information, visit GenScript's official
website:https://www.genscript.com.
About Parkway Laboratories
Parkway Laboratories is one of Singapore's leading private laboratories with a
central reference laboratory which has attained multiple accreditations such as
ISO 15189, College of American Pathologist (CAP), and Joint Commission
International (JCI), ensuring consistent and high-quality services in the areas
of clinical laboratory, histopathology and molecular diagnostics. In addition,
it operates four well-equipped laboratories located within IHH Healthcare's
four hospitals in Singapore, to provide fast and accurate results for patients
and medical practitioners. Parkway Laboratories was the first private
laboratory approved by MOH to commence COVID-19 PCR testing and remains one of
the few high volume laboratories in Singapore supporting the collective
national effort for both COVID-19 PCR and Serology testing. For more
information, please go to www.parkwaylab.com.sg
About the Diagnostics Development (DxD) Hub
The Diagnostics Development (DxD) Hub is a national initiative in Singapore,
led by the Agency for Science, Technology and Research (A*STAR). The DxD Hub
aims to accelerate the transformation of innovations into clinically validated
diagnostic devices that are ready for market adoption. Through impactful
products, empowering local enterprises and anchoring global companies in
Singapore, the DxD Hub contributes to the development of an effective
diagnostic devices ecosystem in Singapore.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead
public sector R&D agency. Through open innovation, we collaborate with our
partners in both the public and private sectors to benefit the economy and
society. As a Science and Technology Organisation, A*STAR bridges the gap
between academia and industry. Our research creates economic growth and jobs
for Singapore, and enhances lives by improving societal outcomes in healthcare,
urban living, and sustainability. A*STAR plays a key role in nurturing
scientific talent and leaders for the wider research community and industry.
A*STAR's R&D activities span biomedical sciences to physical sciences and
engineering, with research entities primarily located in Biopolis and
Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Follow us on
Facebook[https://www.facebook.com/HQastar/]
LinkedIn[https://www.linkedin.com/company/a-star]
Instagram[https://www.instagram.com/astarsingapore/]
YouTube[https://www.youtube.com/astartv]
SOURCE:Genscript
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=388762
Caption: GenScript Biotech Corporation, Parkway Laboratories and the Diagnostics
Development (DxD) Hub collaborate to provide the cPass(TM) SARS-CoV-2
neutralizing antibody test in Singapore.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。